ATE363531T1 - Claudin polypeptide - Google Patents

Claudin polypeptide

Info

Publication number
ATE363531T1
ATE363531T1 AT01964084T AT01964084T ATE363531T1 AT E363531 T1 ATE363531 T1 AT E363531T1 AT 01964084 T AT01964084 T AT 01964084T AT 01964084 T AT01964084 T AT 01964084T AT E363531 T1 ATE363531 T1 AT E363531T1
Authority
AT
Austria
Prior art keywords
claudin
methods
claudin polypeptides
polypeptides
treat
Prior art date
Application number
AT01964084T
Other languages
English (en)
Inventor
Adel Youakim
Robert Dubose
Steven Wiley
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE363531T1 publication Critical patent/ATE363531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01964084T 2000-08-15 2001-08-15 Claudin polypeptide ATE363531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22551300P 2000-08-15 2000-08-15
US22579400P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
ATE363531T1 true ATE363531T1 (de) 2007-06-15

Family

ID=26919667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964084T ATE363531T1 (de) 2000-08-15 2001-08-15 Claudin polypeptide

Country Status (10)

Country Link
US (1) US20080254506A1 (de)
EP (1) EP1311663B1 (de)
JP (1) JP2004519215A (de)
AT (1) ATE363531T1 (de)
AU (2) AU8497701A (de)
CA (1) CA2418725A1 (de)
DE (1) DE60128701T2 (de)
ES (1) ES2284678T3 (de)
MX (1) MXPA03001468A (de)
WO (1) WO2002014499A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833839A1 (fr) * 2001-12-21 2003-06-27 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
US7452877B2 (en) 2002-03-15 2008-11-18 Rytek Methods for treating digestive functional pathologies
FR2844201A1 (fr) * 2002-09-06 2004-03-12 Rytek Compositions pour le traitement de pathologies fonctionnelles digestives
FR2837103B1 (fr) * 2002-03-15 2004-07-09 Rytek Compositions pour le traitement de pathologies fonctionelles digestives
PL375356A1 (en) 2002-05-20 2005-11-28 Immunex Corporation Claudin polypeptides, polynucleotides, and methods of making and use thereof
FR2844713A1 (fr) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Nouvelle cible de l'angiogenese et utilisations
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
FR2879100B1 (fr) 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2009047362A2 (en) 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
JP5234666B2 (ja) * 2009-12-11 2013-07-10 国立大学法人大阪大学 乾癬の判定のための測定方法
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US10746738B2 (en) 2015-02-27 2020-08-18 The Regents Of The University Of Michigan Claudin-1 peptide reagents and methods
US10738079B2 (en) 2017-04-14 2020-08-11 Emory University Compositions and methods for managing respiratory conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019503A4 (de) * 1997-08-06 2003-04-23 Millennium Pharm Inc Die polypeptide tango-71, tango-73, tango-74, tango-76 und tango-83 und die dafür kodierenden nukleinsäure-moleküle
JP2004500011A (ja) * 1998-10-06 2004-01-08 キュラゲン　コーポレイション 新規な分泌タンパク質、およびそれをコードするポリヌクレオチド
US6830894B1 (en) * 1998-11-03 2004-12-14 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
US20040033493A1 (en) * 2001-01-31 2004-02-19 Tchernev Velizar T. Proteins and nucleic acids encoding same

Also Published As

Publication number Publication date
EP1311663B1 (de) 2007-05-30
EP1311663A2 (de) 2003-05-21
WO2002014499A9 (en) 2002-04-18
DE60128701D1 (en) 2007-07-12
CA2418725A1 (en) 2002-02-21
JP2004519215A (ja) 2004-07-02
WO2002014499A2 (en) 2002-02-21
DE60128701T2 (de) 2008-02-07
WO2002014499A3 (en) 2002-10-31
AU2001284977B2 (en) 2005-11-24
ES2284678T3 (es) 2007-11-16
MXPA03001468A (es) 2004-05-04
US20080254506A1 (en) 2008-10-16
AU8497701A (en) 2002-02-25

Similar Documents

Publication Publication Date Title
ATE363531T1 (de) Claudin polypeptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
NO20034056D0 (no) Proliferative sykdommer
ATE396199T1 (de) Antimikrobielles polypeptid
ZA200701656B (en) Humanized anti-cment antagonists
MXPA02004666A (es) Gelatinas recombinantes.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
WO2002079474A3 (en) Human b7 polypeptides
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
EA200400235A1 (ru) Комбинированная терапия для лечения рака
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
ATE537186T1 (de) P53-bindendes polypeptid
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
MXPA03008039A (es) Polipeptidos de serpina humanos.
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
ATE406438T1 (de) Menschliches homolog aus der familie der metalloproteasen
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
WO2003100001A3 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
DE60221501D1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung
DE60118898D1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
DE602004012759D1 (de) Behandlung von fibrosen
ATE414155T1 (de) Moraxella (branhamella) catarrhalis polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties